IS5718A - Notkun alfa1ß1 integrín viðtaka hindra og TGF-ß1 hindra í meðferð nýrnasjúkdóma - Google Patents

Notkun alfa1ß1 integrín viðtaka hindra og TGF-ß1 hindra í meðferð nýrnasjúkdóma

Info

Publication number
IS5718A
IS5718A IS5718A IS5718A IS5718A IS 5718 A IS5718 A IS 5718A IS 5718 A IS5718 A IS 5718A IS 5718 A IS5718 A IS 5718A IS 5718 A IS5718 A IS 5718A
Authority
IS
Iceland
Prior art keywords
alpha1β1
tgf
inhibitors
treatment
receptor antagonists
Prior art date
Application number
IS5718A
Other languages
English (en)
Inventor
Cosgrove Dominic
Original Assignee
Boys Town National Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/292,534 external-priority patent/US6492325B1/en
Priority claimed from PCT/US1999/011073 external-priority patent/WO1999061040A2/en
Application filed by Boys Town National Research Hospital filed Critical Boys Town National Research Hospital
Publication of IS5718A publication Critical patent/IS5718A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • Y10S977/907Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5718A 1998-05-22 2000-11-21 Notkun alfa1ß1 integrín viðtaka hindra og TGF-ß1 hindra í meðferð nýrnasjúkdóma IS5718A (is)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
US09/292,534 US6492325B1 (en) 1998-05-22 1999-04-15 Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (1)

Publication Number Publication Date
IS5718A true IS5718A (is) 2000-11-21

Family

ID=27492055

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5718A IS5718A (is) 1998-05-22 2000-11-21 Notkun alfa1ß1 integrín viðtaka hindra og TGF-ß1 hindra í meðferð nýrnasjúkdóma

Country Status (2)

Country Link
IL (2) IL139687A0 (is)
IS (1) IS5718A (is)

Also Published As

Publication number Publication date
IL139687A (en) 2007-12-03
IL139687A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
IS6411A (is) Kaspasa tálmar og notkun þeirra
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
DK1354888T3 (da) Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
EE200100524A (et) CYP2D6 inhibiitorite kasutamine kombineeritud ravis
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
IS5696A (is) Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
NO20020343D0 (no) Kaspase-inhibitorer og anvendelse derav
IS7040A (is) 5-HT viðtakabindlar og notkun þeirra
NO20001754L (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
PT1212317E (pt) Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
DE69903961D1 (de) Muscarinagonisten und antagonisten
NO20004274D0 (no) Proteaseaktivert reseptor 4 og anvendelse derav
NO20004355D0 (no) Retarderende systemer og anvendelse derav ved oljebrønnsementering
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20000969L (no) Ftalazinderivater og midler for erektil dysfunksjon
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
NO20030156L (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo